What is Resonea?
Established in 2016, Resonea is dedicated to improving performance, safety, and quality-of-life through enhanced sleep health. The company's flagship product, DROWZLE® PRO, is the first FDA-cleared, smartphone-based home sleep test. This innovative technology democratizes access to sleep health services, enabling convenient and safe obstructive sleep apnea detection from the comfort of a patient's home.
How much funding has Resonea raised?
Resonea has raised a total of $348K across 2 funding rounds:
Debt
$150K
Debt
$198K
Debt (2020): $150K with participation from PPP
Debt (2021): $198K led by PPP
What's next for Resonea?
With its large-scale, late-stage funding context and a recent strategic investment, Resonea is well-positioned for significant scaling and market penetration. The company's focus on FDA-cleared, accessible sleep health solutions, particularly for obstructive sleep apnea, aligns with growing healthcare demands for remote diagnostics and personalized wellness. Future growth is likely to involve expanding DROWZLE® PRO's reach, further developing its sleep health platform, and potentially exploring new diagnostic capabilities within the sleep medicine sector.
See full Resonea company page
